

TCRA Deal Summary

We happened to notice a remarkable confluence of circumstances existing today in the huge **\$240 billion** global clinical lab industry whereby up to **\$1 trillion** in uncorrelated recurring cash flow can be generated for our company TCRA over the next 20 years.

What!

Yes, it's based on the **\$7.9 trillion** assured, uncorrelated, recurring revenues global clinical labs will earn from lab tests run on automated analyzers in the next 20 years.

How can that \$7.9 trillion clinical lab revenues produce \$1 trillion in cash flow for TCRA?

The next generation of BIG 4 clinical analyzers will use intellectual property that TCRA owns. If future global lab tests are run on these TCRA-patented automated systems, a royalty rate of **10~20%** will generate up to **\$1 trillion** in royalties for TCRA over the next 20 years.

What does TCRA's intellectual property comprise?

TCRA owns a formidable portfolio of US and international patents on a revolutionary new lab automation system, DLA, *Dark Lab Automation*.

How can current TLA clinical lab automation systems be replaced by DLA in the world's clinical labs?

A standing oligopoly of four huge companies, *Siemens, Roche, Abbott and Danaher*, are the only suppliers in the world of current advanced TLA *Total Lab Automation* clinical lab automation systems. They can employ DLA intellectual property in their next generation of clinical analyzers in their worldwide clinical labs and seamlessly collect the **\$1 trillion** of royalties for TCRA.

What is the Big 4's incentive to adopt DLA?

Three strong incentives: Preserve market share; with **28%** of TCRA the Big 4 will own up to **\$280 billion** of future cash flow on the same day that they announce their plans to replace TLA with DLA in their next generation clinical analyzers; 160,000 Rh babies' lives will be saved every year.

Who are the TCRA shareholders?

After the ILBOW Philanthropy will have **50%**, BIG4 **28%**, Top PE firms **9%**, Early investors **11%**.

What will be the effect of their announcements on TCRA's company value?

Investors, once confident that the Big 4 can collect up to **\$1 trillion** in royalties for TCRA in the next 20 years, will value TCRA at **~\$300 billion**.

How can liquidity be achieved for TCRA shareholders?

The bylaws of the company will establish company policy whereby the Big 4 and underwriter firms who are shareholders will seek tender offers for any shareholder who wishes to cash out. And manage the sale at the best price.

What is the amazing Golden Nugget of this high finance deal?

Wonderfully, the first recipient of philanthropy will be WIRhE, who will receive an immediate endowment of **\$10 billion**. Enough to fund their Rh program in perpetuity. This will result in the eradication of Rh Hemolytic Disease of the Newborn from the whole world, saving **140,000 babies'** lives every year into the future.